Article

Glaucoma surgery techniques compared in large-scale Medicare patient study

The claims records of 14,491 Medicare beneficiaries with glaucoma who were treated with an incisional surgery, either primary trabeculectomy, trabeculectomy in the presence of scarring from previous ocular surgery or trauma, or implantation of a glaucoma drainage device between 1994 and 2003 were evaluated.

San Francisco-The claims records of 14,491 Medicare beneficiaries with glaucoma who were treated with an incisional surgery, either primary trabeculectomy (PT), trabeculectomy in the presence of scarring from previous ocular surgery or trauma (TS), or implantation of a glaucoma drainage device (GDD) between 1994 and 2003 were evaluated by Frank A. Sloan, PhD, and colleagues.

It was found that although adverse outcomes were uncommon for all three options, rates of severe outcomes, less severe outcomes, and progression to low vision or blindness were higher for individuals who received GDD than for those who received PT or TS.

Each surgical technique was designed to improve drainage of fluid from the eye to reduce IOP. In both PT and TS a small portion of the trabecular meshwork is removed to increase fluid flow, and in GDD a tiny implanted shunt is used to bypass the trabecular meshwork and redirect fluid flow. It was stated by some studies that GDD performed earlier in complicated glaucoma might provide benefit with fewer outcomes, which is why this study compared GDD, PT, and TS.

Study patients were at least 68 years of age but not older than 96 during the time of evaluation. Study population was diverse, however, the patients treated with GDD were disproportionately African-American, a group at higher risk than other ethnicities of developing glaucoma-related blindness.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.